Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

X4 Pharmaceuticals Inc (XFOR) NPV

Sell:$13.70 Buy:$14.99 Change: $0.21 (1.48%)
NASDAQ:0.26%
Market closed |  Prices as at close on 12 November 2019 | Switch to live prices |
Sell:$13.70
Buy:$14.99
Change: $0.21 (1.48%)
Market closed |  Prices as at close on 12 November 2019 | Switch to live prices |
Sell:$13.70
Buy:$14.99
Change: $0.21 (1.48%)
Market closed |  Prices as at close on 12 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

X4 Pharmaceuticals, Inc., formerly Arsanis, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases including primary immunodeficiencies and cancer. The Company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. Its product candidates include X4P-001, X4P-002 and X4P-003.

Contact details

Address:
955 Massachusetts Ave Ste 4
CAMBRIDGE
02139-3108
United States
Telephone:
+1 (857) 5298300
Website:
www.x4pharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XFOR
ISIN:
US98420X1037
Market cap:
$176.88 million
Shares in issue:
12.46 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Michael Wyzga
    Chairman of the Board
  • Paula Ragan
    President, Chief Executive Officer, Secretary, Director
  • Adam Mostafa
    Chief Financial Officer, Treasurer, Assistant Secretary
  • Renato Skerlj
    Senior Vice President - Research and Development
  • Derek Meisner
    General Counsel
  • E. Lynne Kelley
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.